Skip to main content

Table 3 Choice of antiretroviral regimen

From: UK national clinical audit: management of pregnancies in women with HIV

CD4 count (cells/mm3) Viral load (copies/mL) BHIVA recommendationa Number of women In accordance with recommendation
≤350 - TVD/FTC, ABC/3TC or ZDV/3TC + EFV, NVP or bPI 214 93%
>350 >100,000 TFV/FTC, ABC/3TC or ZDV/3TC + bPI 11 100%
10,000 – 100,000 As above or ZDV/3TC/ABC 81 99%
<10,000 As above or ZDV monotherapy 162 98%
unknown - 84 -
  1. TVD truvada, FTC emtricitabine, ABC abacavir, 3TC lamivudine, ZDV zidovudine, EFV efavirenz, NVP nevirapine, bPI boosted protease inhibitor
  2. aRaltegravir was accepted as an alternative to EFV/NVP/bPI when started after the first trimester